A Phase 1 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs CC 92480 (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Celgene Corporation
- 07 Jan 2019 According to a Celgene Corporation media release, data from the study is expected in 2019.
- 30 Apr 2018 Planned number of patients changed from 160 to 80.
- 09 Mar 2018 Planned End Date changed from 1 Jun 2022 to 1 Mar 2020.